Compare ALLO & PKOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | PKOH |
|---|---|---|
| Founded | 2017 | 1907 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 299.5M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | PKOH |
|---|---|---|
| Price | $1.69 | $25.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 1 |
| Target Price | $8.27 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 7.1M | 20.0K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | N/A | ★ 30.26 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $1,592,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.72 |
| P/E Ratio | ★ N/A | $14.86 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $15.52 |
| 52 Week High | $3.78 | $26.31 |
| Indicator | ALLO | PKOH |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 71.51 |
| Support Level | $1.62 | $21.17 |
| Resistance Level | $1.97 | $25.24 |
| Average True Range (ATR) | 0.16 | 0.96 |
| MACD | -0.00 | 0.27 |
| Stochastic Oscillator | 42.72 | 84.39 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.